Common obesity is a polygenic disorder, resulting from a complex interplay between genetics and environmental factors. Since 2007, genome-wide association studies (GWAS) utilized DNA to assess millions of single nucleotide polymorphisms (SNPs) in large cohorts and have identified \>250 loci associated with body mass index (BMI)^[@R1]^. However, elucidating the functional link between the causal variant and BMI has been a challenge.

Recently, we found that the expression of genes located in closed proximity to type 2 diabetes GWAS SNPs was significantly enriched in insulin-secreting beta cells, but not in insulin sensitive tissues^[@R2]^. This was performed using PCR-free technology in various human tissues, which has the advantage of avoiding genetic material amplification^[@R2]^. This study confirmed that the pathophysiology of common type 2 diabetes caused by the genetic variants acts through insulin-secreting cells^[@R2]^. In obesity, by using public gene expression microarray data, a recent study has demonstrated that the expression of genes, located nearby GWAS-identified BMI-associated SNPs, is significantly enriched in the central nervous system^[@R3]^. These findings were consistent with studies from monogenic forms of obesity, as the implicated genes, like *MC4R*, *POMC*, and *LEPR*, play a key role in the central nervous system, regulating appetite and body weight. Here, using the same strategy as previously implemented^[@R2]^, we aimed to confirm and refine this enrichment of BMI-associated gene expression in the central nervous system. In addition, we used the French D.E.S.I.R. study to assess the association between BMI and several genetic risk scores (GRS), including alleles increasing BMI closest to the genes with the highest expression level and specificity in two brain regions of interest.

Methods {#S1}
=======

Expression study of obesity/BMI susceptibility genes {#S2}
----------------------------------------------------

The expression study of obesity/BMI susceptibility genes was performed using the NanoString technology (Seattle, WA, USA) which is a multiplex digital quantification of nucleic acids, in a large panel of human tissues, as previously described^[@R2]^. Our panel included human RNA from colon, small intestine, liver, kidney, adipose tissue, primary pre-adipocytes, mature adipocytes, lung, skeletal muscle, heart, brain, substantia nigra, hippocampus, dorsal root ganglion, insula, hypothalamus, pituitary gland, caudate nucleus, frontal lobe, pancreatic islets, pancreatic beta cells, exocrine pancreas and the pancreatic beta-cell line EndoC-βH1^[@R2]^. The probes were designed to target 111 genes, including five housekeeping genes for normalization^[@R2]^ and 106 susceptibility genes for obesity/BMI previously published in GWAS ([Supplementary Table 1](#SD1){ref-type="supplementary-material"})^[@R3]--[@R11]^. Notably, as the probes were designed in 2016, we were unable to assess novel susceptibility genes for obesity/BMI that were identified in the latest GWAS^[@R1],[@R12]^. The expression profiles of obesity/BMI susceptibility genes were analyzed using heat maps, as previously described^[@R2]^. We established a threshold to classify the expression enrichment of obesity/BMI susceptibility genes in each tissue of the panel^[@R2]^. This threshold was defined as the average gene expression across all tissues, plus one standard deviation (SD). A Fisher\'s exact test was applied to test the expression enrichment of the gene set in each tissue of the panel^[@R2]^.

Calculation of GRS {#S3}
------------------

Five GRS were calculated as the sum of five alleles increasing BMI closest to the five genes with the highest expression level and specificity in human insula and substantia nigra (top-1→top-5 genes, top-6→top-10 genes, top-11→top-15 genes, top-16→top-20 genes and top-21→top-25 genes; [Supplementary Table 2](#SD1){ref-type="supplementary-material"}).

Study population {#S4}
----------------

We used genetic and clinical data from the D.E.S.I.R. cohort^[@R13]^. We analyzed 4,236 European-Caucasian individuals (mean±SD age of 47±10 years; mean±SD BMI of 24.7±3.8 kg/m^2^). The ethnicity of the participants was assessed as previously described^[@R13]^. All participants provided written informed consent and the study protocol was approved by the Ethics Committee for the Protection of Subjects for Biomedical Research of Bicêtre Hospital (France).

Genotyping {#S5}
----------

The genotyping of the 25 SNPs included in our GRS was performed using Metabochip DNA arrays (Illumina), as previously described^[@R13]^. The genotyping success rate in the study was \>99% for the 25 SNPs, and no departures from Hardy-Weinberg equilibrium were observed. We excluded from the analysis the individuals with ≥2 missing SNP calls. For individuals with only one missing SNP call, the missing alleles were assigned to the most common allele.

Statistical analyses {#S6}
--------------------

The association between each of the five GRS and BMI was assessed through a linear regression adjusted for age and sex, using the IBM SPSS software (version 22).

Results {#S7}
=======

We assessed the expression of 106 genes ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}) located close to GWAS-identified SNPs associated with obesity/BMI in our panel of human tissues using the PCR-free NanoString technology. The heat map in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"} shows the expression profile of the 106 susceptibility genes for obesity and/or BMI in the panel. The expression of the 106 genes was strongly enriched in the insula (*p*=4.7×10^-9^) and substantia nigra (*p*=6.8×10^-7^) ([Figure 1](#F1){ref-type="fig"}). We identified two other tissues with a less significant expression enrichment pattern for BMI/obesity susceptibility genes, namely the whole brain (*p*=7.5×10^-4^) and hippocampus (*p*=7.5×10^-4^) ([Figure 1](#F1){ref-type="fig"}).

In order to correlate our enrichment expression analysis and genetic association data, we next generated five GRS, each summing five obesity/BMI associated alleles (found by GWAS) closest to the five genes with the highest expression level and specificity in human insula and substantia nigra. Namely, GRS-1 included alleles nearby top-1 to top-5 insula/substantia nigra enriched genes, GRS-2 included alleles nearby top-6 to top-10 genes, GRS-3 included alleles nearby top-11 to top-15 genes, GRS-4 included alleles nearby top-16 to top-20 genes and GRS-5 included alleles nearby top-21 to top-25 genes ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). We assessed the association of each of these GRS with BMI in 4,236 European individuals. We found that GRS-1 (including effect alleles close to *CADM2*, *NUDT3*, *FTO*, *FAIM2* and *NRXN3*) had the strongest association with an increased BMI (per additional risk allele: β=0.188±0.039 kg/m^2^, *p*=1.3×10^-6^; [Table 1](#T1){ref-type="table"}). This was followed by GRS-3 (including effect alleles close to *NAV1, NEGR1*, *RALYL*, *LRP1B* and *STXBP6*; β=0.154±0.040 kg/m^2^, *p*=1.5×10^-4^; [Table 1](#T1){ref-type="table"}) and GRS-2 (including effect alleles close to *C6orf106, ETV5*, *ERBB4*, *GRID1* and *HIP1*; β=0.138±0.044 kg/m^2^, *p*=0.0016; [Table 1](#T1){ref-type="table"}). GRS-4 and GRS-5 did not associate with BMI in our study (*p*\>0.01; [Table 1](#T1){ref-type="table"}). Of note, *FTO* SNP alone had the following effect on BMI in our study: β=0.265±0.081 kg/m^2^, *p*=0.0010.

Discussion {#S8}
==========

The physiopathology of obesity is still an area of immense controversy. Although there is a general agreement that the heritability of obesity is substantial, its contribution to energy imbalance remains largely elusive. Since the 1990s, considerable progress has been made in the elucidation of the most extreme forms of early-onset obesity, which are often monofactorial. These monofactorial forms of obesity are primarily caused by defects in appetite regulation, as most of the monogenic obesity genes are part of the leptin-melanocortin pathway that mainly acts within the hypothalamus. However, it remains unknown whether these mechanisms of disease are relevant to common obesity. Of note, under clinical protocols, unlike patients with monogenic obesity who display constant hyperphagia, obese individuals do not exhibit free-running behavior^[@R14]^. Conversely, it has been demonstrated that eating addiction strongly contributes to obesity^[@R15],[@R16]^.

Our results have unambiguously shown that the expression of obesity/BMI susceptibility genes is strongly enriched in two regions of the brain, the insula and substantia nigra, which are related to addiction and reward. Moreover, the strongest gene enrichment in those two brain regions concerns genes within loci that have the strongest impact on BMI, including *FTO*, which is the most potent locus in common obesity. The insula (or insular cortex) is located within the cerebral cortex and is subdivided into two main groups, the granular and agranular insula^[@R17]^. The agranular insula likely plays a key role in emotion and motivation, in addition to addiction and the conscious urges to take drugs^[@R17]^. This is due to the strong dopaminergic innervation within the agranular insula and its high density of D1 dopamine receptors, endogenous opioids and µ-opioid receptors^[@R17]^. Moreover, the substantia nigra, which is part of the basal ganglia located in the midbrain, also plays a role in addiction, motivation and reward-seeking behavior and displays a high density of dopaminergic neurons^[@R18],[@R19]^. Previous studies showed that the obesity/BMI-associated locus in *FTO* (*i.e.* the top 3 gene enriched in insula and substantia nigra in the present study) impacts eating disorders^[@R20],[@R21]^, including binge eating, which was found to disrupt dopaminergic signaling in the human brain^[@R22]^.

The main limitation of our study is that we predominantly focused on genes closest to the BMI-associated SNPs found by GWAS. This approach excluded all genes located in the same topologically associating domains (TADs) as the BMI-associated SNPs, namely the genes that may in theory be regulated by these SNPs, and expression quantitative trait loci (eQTL) particularly within brain regions. However, using publicly available data from the Genotype-Tissue Expression (GTEx) project, in 1,497 human brain tissue samples, out of the 25 BMI-associated SNPs listed in the five GRS, only four SNPs had a significant effect on mRNA expression, thus, limiting the second option. It is important to note that when we analyzed all available tissues (*i.e.* 10,294 human tissue samples with donor genotype), we found no significant eQTLs for 15 of the 25 BMI-associated SNPs listed in the five GRS. Of the remaining 10 BMI-associated SNPs, eight SNPs (rs206936, rs1558902, rs205262, rs7599312, rs3101336, rs11191560, rs1000940, rs16951275) had a significant effect on the expression of their nearest gene (*NUDT2*, *FTO*, *C6orf106*, *ERBB4*, *NEGR1*, *NT5C2*, *RABEP1*, *MAP2K5*, respectively) in at least one of the assessed human tissues. These results were in line with our strategy, which focused on investigating the expression of genes closest to BMI-associated SNPs. Assessing the expression of all genes located in the same TAD as the BMI-associated SNPs would have reduced or eliminated the signal of expression enrichment in brain regions. Of note, our library also included *IRX5* located in the same TAD as *FTO*, which was suggested to play a role in weight regulation through adipocyte thermogenesis^[@R23]^. The highest expression of *IRX5* was actually found in pancreatic beta cells, exocrine pancreas, lung and heart, and to a lesser extent in the brain areas ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

In conclusion, the present study suggests that the genetic component of common obesity has an impact on eating addiction and reward behaviors in the central nervous system. Further epidemiological studies with relevant food behavior phenotypes are necessary to confirm these findings.
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![Enrichment analysis of the expression of 106 susceptibility genes for obesity/BMI in the panel of human organs, tissues and cells.\
The black vertical line denotes a *p*-value of 0.05.\
***EndoC-βH1***, human pancreatic beta-cell line; ***FACS***, fluorescence-activated cell sorting; ***LCM***, laser capture microdissection.](EMS83436-f001){#F1}

###### Association between several GRS and BMI in the D.E.S.I.R. study, adjusted for age and sex.

               SNPs increasing BMI   Closest genes   *n*     Per allele effect size ± SE   *p*-value
  ------------ --------------------- --------------- ------- ----------------------------- --------------
  **GRS-1**    rs13078960            *CADM2*         4,236   0.188 ± 0.039                 1.3 × 10^-6^
  rs206936     *NUDT3*                                                                     
  rs1558902    *FTO*                                                                       
  rs7138803    *FAIM2*                                                                     
  rs7141420    *NRXN3*                                                                     
  **GRS-2**    rs205262              *C6orf106*      4,236   0.138 ± 0.044                 1.6 × 10^-3^
  rs1516725    *ETV5*                                                                      
  rs7599312    *ERBB4*                                                                     
  rs7899106    *GRID1*                                                                     
  rs1167827    *HIP1*                                                                      
  **GRS-3**    rs2820292             *NAV1*          4,235   0.154 ± 0.040                 1.5 × 10^-4^
  rs3101336    *NEGR1*                                                                     
  rs2033732    *RALYL*                                                                     
  rs2121279    *LRP1B*                                                                     
  rs10132280   *STXBP6*                                                                    
  **GRS-4**    rs11727676            *HHIP*          4,236   0.055 ± 0.048                 0.25
  rs11191560   *NT5C2*                                                                     
  rs2075650    *TOMM40*                                                                    
  rs1000940    *RABEP1*                                                                    
  rs1528435    *UBE2E3*                                                                    
  **GRS-5**    rs9400239             *FOXO3*         4,235   0.072 ± 0.034                 0.037
  rs657452     *AGBL4*                                                                     
  rs11583200   *ELAVL4*                                                                    
  rs887912     *FANCL*                                                                     
  rs16951275   *MAP2K5*                                                                    

***BMI***, body mass index; ***GRS***, genetic risk score; ***SE***, standard error; ***SNP***, single nucleotide polymorphism.
